ArticleMedicine2026
Association between ankylosing spondylitis and hearing loss: A Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Observational studies have suggested a potential link between ankylosing spondylitis (AS) and hearing loss. However, this association remains controversial due to potential drug-induced ototoxicity from treatments. Therefore, we employed a Mendelian randomization (MR) approach to evaluate the association between AS and hearing loss from a genetic perspective. This MR study utilized summary data from genome-wide association studies on AS and hearing loss, including sensorineural hearing loss (SNHL) and conductive hearing loss (CHL). The primary analysis was conducted using the inverse-variance weighted method. The primary analysis showed a causal effect of AS on both SNHL (odds ratio [OR] = 1.121, 95% confidence interval [CI]: 1.042-1.206, P = .002) and CHL (OR = 1.387, 95% CI: 1.123-1.712, P = .002). After excluding chromosome 6 variants, the association with CHL persisted (OR = 1.675, 95% CI: 1.212-2.315, P = .002), while the effect on SNHL was no longer significant (OR = 1.054, 95% CI: 0.942-1.181, P = .357). The primary inverse-variance weighted analysis showed no causal effect of SNHL on AS (OR = 0.984, 95% CI: 0.892-1.086, P = .747). Sensitivity analyses found no evidence of horizontal pleiotropy. This MR study suggests that AS is causally associated with higher risks of CHL and SNHL. The association with CHL appears independent of the chromosome 6 human leukocyte antigen region, whereas the risk for SNHL is largely driven by this region. These findings suggest that targeted audiometric evaluations should be considered for symptomatic patients with AS. Further studies are required to explore the specific mechanisms linking AS to different types of hearing loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.